GlaxoSmithKline poached Pfizer's RNA and viral vaccines leader Phil Dormitzer, M.D., Ph.D., to shore up its vaccine business as it's lost many research staffers this past year. Parthenon Therapeutics snagged Johnson & Johnson's global head of cell therapy platform and discovery, Tamas Oravecz, Ph.D. And Rafael parted ways with five execs and reinstalled telecom tycoon Howard Jonas as CEO.
It took 17 years to get its first FDA greenlight. Three months later, Cara Therapeutics founding CEO Derek Chalmers exits the top perch as LEO Pharma's U.S. CEO and president enters the role.
Athira Pharma's CEO resigns after investigation confirms she altered research during graduate school. vTv Therapeutics named healthcare investor Deepa Prasad its new CEO and president. Opus Genetics snagged a new chief scientific officer and chief operating officer.
Kojin Therapeutics likes to do things differently: Its platform is looking to for the first time drug the ferroptosis-sensitive cell state and treat a host of diseases, and, now, an all-woman leadership team will help make that happen.
Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., will retire at the end of the year, following the lead of CEO Alex Gorsky, who also departs soon. Emile Nuwaysir led Bayer's $1 billion bet on Parkinson's disease, and now he heads up gene therapy biotech Ensoma. Genentech's early cancer research leader Shiva Malek jumps to Novartis' NIBR oncology unit.